Abstract 10323: Growth Differentiation Factor-15 (GDF-15) is Involved in Muscle Atrophy of Patients With Cardiovascular Diseases

• Published in: Circulation (New York, N.Y.) N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A10323-A10323
• Main Authors: Nakajima, Toshiaki, Ogawa, Hironaga, Sawaguchi, Tatsuya, Obi, Syotarou, Ikuko, Shibasaki, Takei, Yuusuke, Sakuma, Satoshi, Toyoda, Shigeru, Nishimura, Masao, Fukuda, Hirotsugu, Inoue, Teruo
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.140.suppl_1.10323

IntroductionMuscle atrophy and sarcopenia are predictors of ADL and survival in patients with cardiovascular diseases, and it increases the risk of complications and mortality when invasive treatment such as cardiac operation is performed. The growth and differentiation factor 15 (GDF-15) has been associated with various pathophysiological conditions including atherosclerosis, heart failure and cachexia.HypothesisTo investigate the involvement of GDF-15 on muscle atrophy and sarcopenia in cardiovascular surgery patients.MethodsPreoperative skeletal muscle index (SMI) measured by bioelectrical impedance analysis, handgrip strength (HGS), 4 m gait speed, biochemical measurements, and anterior thigh muscle thickness (MTh) measured by echocardiography were assessed in 72 patients (42 males, average age 69.9 years) with surgery for cardiovascular diseases. Sarcopenia was diagnosed based on European Working Group on Sarcopenia. The serum GDF-15 concentration was determined by enzyme-linked immunosorbent assay.ResultsGDF-15 levels significantly correlated with age, BNP, estimated glomerular filtration rate (eGFR), and had a significant negative correlation with SMI, HGS, and anterior thigh muscle thickness (MTh). In multivariate analysis, GDF-15 levels were extracted as a factor defining HGS and anterior MTh even if corrected with age, gender and BMI (HGS; β=-0.237, p=0.041; anterior MTh; β =-0.390, p=0.004). On the other hand, eGFR and anterior MTh were extracted as independent factors to define GDF-15 concentration in blood (eGFRβ =-0.597, p=0.000; anterior MThβ=-0.272, p=0.019). The prevalence of sarcopenia was 37%. The GDF-15 levels in sarcopenia patients were significantly higher than in non-sarcopenia patients (male without sarcopenia 1483 ± 1125 pg/ml, male with sarcopenia 3053±2346 pg/ml, p